ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.971,60
-0,16%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) News

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OCUL
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202422h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
07/05/202422h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
07/05/202422h05GlobeNewswire Inc.Ocular Therapeutix™ Reports First Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
07/05/202422h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCULOcular Therapeutix Inc
07/05/202402h16GlobeNewswire Inc.Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
06/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
03/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024NASDAQ:OCULOcular Therapeutix Inc
01/05/202413h30GlobeNewswire Inc.Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
11/03/202421h23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
11/03/202421h12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCULOcular Therapeutix Inc
11/03/202421h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
11/03/202411h39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:OCULOcular Therapeutix Inc
27/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
27/02/202402h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
27/02/202402h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
27/02/202402h04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
27/02/202402h02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
22/02/202414h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
22/02/202413h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
19/02/202415h00PR Newswire (US)AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic ConjunctivitiNASDAQ:OCULOcular Therapeutix Inc
15/02/202414h00GlobeNewswire Inc.Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial OfficerNASDAQ:OCULOcular Therapeutix Inc
15/02/202401h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCULOcular Therapeutix Inc
13/02/202413h37GlobeNewswire Inc.Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
07/02/202400h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/02/202400h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/02/202400h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/02/202400h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/02/202400h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
05/02/202422h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
05/02/202422h39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
 Showing the most relevant articles for your search:NASDAQ:OCUL

Kürzlich von Ihnen besucht

LSE
33GX
Agric Dev Bk 26
AMEX
USFR
WisdomTree Floating Rate...
LSE
33JT
Arkle 2bs
BIT
F11969
Vontobel Financial Produ...
ASX
HEGN
TSXV
RECO.WT.A
Reconnaissance Energy Af...
ASX
RIOLOK
COIN
OYSBTC
BIT
STRN5S
Societe Generale Effekten
USOTC
SLNFF
Solution Financiall (PK)
EU
NL0011614060
Netherlands Government/t...
NYSE
BWG
BrandywineGlobal Global ...
LQID
WABIBTC
LSE
94MF
Lloyds Bk.24
BOV
BSHY39Q
BlackRock Institutional ...
USOTC
EDDYF
Edison Lithium (QB)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten